China allegations 'shameful' for GSK as probe deepens
This article was originally published in Scrip
Executive Summary
Still-emerging revelations of suspected fraud and corrupt practices involving a number of senior executives at GlaxoSmithKline's Chinese operations are becoming a major embarrassment for the firm, which has described the widening allegations as "shameful".